Document is current

Article History

Accepted: 6 November 2023

First Online: 30 November 2023

Declarations

:

: This study was approved by the Institutional Review Board of the NCI (IRBd21-247).

: The datasets and Markov model used and analysed during the current study are available from the corresponding author on reasonable request.

: The cost-effectiveness model was developed in Microsoft Excel 365 (Microsoft Corporation). Any additional information about model programming is available from the corresponding author upon request.

: Not applicable.

: Not applicable.

: Valesca P. Retèl and Wim H. van Harten received unrestricted research grants from Agendia BV and Intuitive BV, outside the scope of the current research. Joost G.E. Verbeek, Karen van der Sluis, Marieke A. Vollebergh and Johanna W. van Sandick declare that they have no conflicts of interest in relation to this work.

: The PERISCOPE II study is part of a Coverage with Evidence Development Programme, granted by the Dutch Ministry of Health, whereas trial and research costs have been granted by ZonMw (grant no. 843004016). Moreover, the PERISCOPE II study is funded by the Dutch Cancer Society. The funding bodies did not have any role in the design, collection, management, analysis, and interpretation of the data.

: JV, VR, WvH, and JvS have made substantial contributions to the design and concept of this study. JV, KvdS, and VR collected and analysed data from literature and the ‘systemic chemotherapy only’ and ‘CRS/HIPEC’ cohorts. JV and VR constructed the Markov model, and JV wrote the first draft of this manuscript. All authors revised and contributed to subsequent versions of the manuscript, and the final version was approved by all authors.